bulk Pranlukast Raw material powder supplier | Ausreson

CAS: 103177-37-3

MF: C27H23N5O4

MW: 481.5

EINECS: 808-178-9

Specification: 99% min Pranlukast powder

Sample: Pranlukast powder Avaliable

Packaging: 1kg/bag, 25kg/drum

Brand: Ausreson

MOQ: 1 kg

Appearance: white powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Last updated: March 2026

Pranlukast Powder Usage and Synthesis.

It is clinically used to prevent bronchial asthma. 225mg orally once, twice a day, after breakfast and dinner. There may be gastrointestinal reactions, including nausea, vomiting, abdominal pain, diarrhea or constipation, and sometimes fever, rash, pruritus and abnormal liver function such as elevated serum aminotransferase or bilirubin. Pregnant women should use with caution, and the elderly should reduce the amount as appropriate.

This product does not relieve asthma that has already occurred. Currently, the three main leukotriene receptor antagonists are used as follows:

1, zafirlukast: Effective in mild to moderate asthma, can cause dose-dependent improvement in lung function, and can reduce the amount of beta agonists. The absorption of this product is affected by food, so it should not be taken with food. 20mg orally, twice a day.

2. montelukast: It is effective for adults and children with intermittent or persistent asthma. This product is approved by the FDA for the treatment of children aged 6 to 12 years. The absorption of this product is not affected by food, and can be taken with food. 10mg orally, once a day.

3. pranlukast: For mild to moderate asthma, Pranlukast can increase the maximum expiratory flow rate and improve asthma symptoms, and can be used as a daily medication for chronic asthma. Orally 450mg twice a day.

Uses of Pranlukast.

Prelunkast is an anti-asthmatic drug used in the treatment and prevention of bronchial asthma in patients.

The main component of prekast is Prekast hemihydrate. The commonly used dosage form of the drug is capsule, of which the character of the capsule is, the content is like white to light yellow powder, in addition, the drug is a prescription drug, the drug needs to consult the doctor before taking the drug.

How Pranlukast Restores Breathing

• Blocking Leukotriene Receptors: Leukotrienes are 1000x more potent than histamine in causing bronchoconstriction. Pranlukast powder binds to the CysLT1 receptor, preventing these molecules from triggering airway spasms and narrowing.

• Reducing Mucosal Edema: By decreasing vascular permeability, Pranlukast helps "drain" the fluid buildup in the nasal and bronchial linings. In 2026, it is a leading intervention for Persistent Nasal Congestion that doesn't respond to antihistamines.

• Eosinophil Infiltration Control: It inhibits the migration of eosinophils (inflammatory white cells) into the lungs. This makes it a critical 2026 tool for preventing the remodeling of airway tissue in chronic asthmatics.

• Non-Steroidal Safety Profile: Pranlukast offers a potent anti-inflammatory effect without the long-term metabolic side effects associated with inhaled or oral corticosteroids, a major selling point in 2026's "Clean Pharma" trend.

• Optimized Particle Size (Micronization): For 2026 respiratory formulations, surface area is everything. Micronized Pranlukast Powder ensures faster dissolution and more consistent absorption in the gastrointestinal tract, leading to stable plasma levels.

• High Polymorphic Stability: Premium 2026 powders are processed to maintain the most stable Polymorph Form, ensuring that the powder does not degrade or lose efficacy when stored in humid or high-temperature environments.

• Ultra-Low Impurity Profile: Advanced Recrystallization Technology ensures that the powder is free from residual synthesis catalysts, meeting the strict 2026 ICH (International Council for Harmonisation) guidelines.

The 2026 "Pulmo-Purity" Checklist

• ≥ 99.0% Purity (HPLC Verified): The mandatory pharmaceutical benchmark for Pranlukast Hemihydrate.

• Heavy Metal & Residual Solvent Testing: Must meet 2026 global safety standards (Lead <0.5ppm, Zero Hexane/Methanol residues).

• White to Light Yellow Crystalline Appearance: A visual indicator of high-purity synthesis and proper storage.

• Comprehensive COA (Certificate of Analysis): Ensuring transparency in moisture content, ash, and related substances.

Frequently Asked Questions

In 2026, we categorize them as "Chemical Cousins." While both are leukotriene receptor antagonists, Pranlukast was the first developed and is often preferred in certain clinical settings for its specific binding affinity and long-standing safety record in pediatric populations in Asia.

Yes. In 2026, it is a highly effective treatment for Allergic Rhinitis. It is particularly useful for patients whose primary symptom is nasal congestion rather than just itching or sneezing.

Pranlukast is a preventative medication. While some effects are felt within hours, the full clinical benefit for asthma and chronic inflammation usually peaks after 2–4 weeks of consistent daily use.

For B2B manufacturing purposes, the powder is typically formulated into doses of 112.5mg to 225mg, taken twice daily after meals to optimize absorption.

Оптовый поставщик сырья порошка Пранлукаст | Ausreson
Fournisseur de poudre de matière première Pranlukast en vrac | Ausreson
Großhandelslieferant für Pranlukast-Rohstoffpulver | Ausreson
Proveedor de materia prima en polvo de Pranlukast a granel | Ausreson
Fornecedor de matéria-prima em pó de Pranlukast a granel | Ausreson